Brian R. Bettencourt

Author

Also Known As

B. Bettencourt, B. R. Bettencourt, B.R. Bettencourt, BRIAN BETTENCOURT, BRIAN R. BETTENCOURT, Bettencourt, Brian R., Brian Bettencourt, Brian R Bettencourt, Brian R. Bettencourt

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)University of Chicago Covance (United Kingdom)Harvard University Boston University

About

Brian R. Bettencourt is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, natural sciences, and gene expression.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.8K
2	Natural Sciences	8	8	795
3	Biochemistry	4	4	849
4	Engineering	2	2	118
5	Public Health	1	1	50

Brian R. Bettencourt

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho, David Adams, Ana Silva, New England Journal of Medicine	2013	947
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 Kevin Fitzgerald, Suellen White, Anna Borodovsky, New England Journal of Medicine	2016	738
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, The Lancet Metabolic SyndromeOxysterolBiochemistryCardiovascular DiseaseHealthy Volunteers	2013	571
Comparative genome sequencing of <i>Drosophila pseudoobscura</i> : Chromosomal, gene, and <i>cis</i> -element evolution Stephen Richards, Yue Liu, Brian R. Bettencourt, Genome Research	2005	506
Pleiotropic Effects of Vitamin D on Osteoblast Gene Expression Are Related to the Proliferative and Differentiated State of the Bone Cell Phenotype: Dependency upon Basal Levels of Gene Expression, Duration of Exposure, and Bone Matrix Competency in Normal Rat Osteoblast Cultures* Thomas A. Owen, Michael S. Aronow, Leesa M. Barone, Endocrinology	1991	350
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study Ole B. Suhr, Teresa Coelho, Juan Buades, Orphanet Journal of Rare Diseases	2015	316
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate Tracy Zimmermann, Verena Karsten, Amy Chan, Molecular Therapy	2017	202
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria Abigail Liebow, Xingsheng Li, Timothy Racie, Journal of the American Society of Nephrology Translational MedicineBiochemistryPrimary HyperoxaluriaGlycolate OxidaseLiver Physiology	2016	198
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia Paul J. Schmidt, Iva Toudjarska, Anoop K. Sendamarai, Blood	2012	196
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients Jens Gottlieb, Martin R. Zamora, Tony N. Hodges, The Journal of Heart and Lung Transplantation Lung TransplantationRespiratory DiseasesRespiratory InfectionVirologyInfectious Respiratory Disease	2015	156

Page 1